Nodality, Inc., which is focused on solving drug development challenges,
announced today the launch of its PathPro™ product line. PathPro
products leverage the unique capabilities of Nodality’s proprietary
Single Cell Network Profiling (SCNP) technology, offering predefined
multiparametric flow cytometry-based experimental panels. These panels
allow us to study customer inhibitor activity and identify disease
subgroups and differential responses in pathways or diseases. Nodality
has introduced its first three PathPro products – the PathPro™ JAK-STAT
panel, PathPro™ TLR and the PathPro™ AML panels – and these will be
followed by additional products throughout 2015.
“Nodality’s SCNP technology has been successfully applied and proven in
autoimmune diseases, hematological cancers, and immuno-oncology. Based
on this substantial and growing track record, we are expanding our
offerings by introducing predefined experimental panels in
cost-effective and highly targeted areas,” said Laura Brege, CEO and
President of Nodality, Inc. “We believe the launch of our new PathPro
products will accelerate familiarity with our technology advantages
among our target customer base – pharmaceutical and life science
companies – and lead to further demand for our customized services based
on each customer’s initial experience with the PathPro products.”
Nodality’s PathPro products are based on the Company’s broad knowledge
and experience in diverse signaling pathways and in interrogating
signaling at the single cell level in numerous cell types. For each
PathPro product, customers are able to select modulators, pathways, cell
types and donor sample types to be applied in targeted, small-scale
studies. The results provide critical insights into the functional
impact of drug candidates in disease sub-groups and differential
response, pathway-specific profiles and/or disease profiles, while
addressing mechanism of action (MOA), efficacy (IC50s) and comparison of
compound activities.
Nodality’s first three PathPro products are:
|
|
|
•
|
|
PathPro™ JAK-STAT panel
|
|
|
|
|
|
|
|
|
|
|
|
Nodality's PathPro Janus Kinase-Signal Transducer and Activator of
Transcription (JAK-STAT) panel enables simultaneous measurements
of signaling and compound activity in different cell subsets
(monocytes, lymphocytes, and B and T cells) in the context of
JAK-STAT signaling. Performance of modulators (interleukins,
interferons and GM-CSF) is measured via readouts in the activity
of the primary STAT protein signals. The JAK-STAT signaling
pathway is essential for hematopoiesis and plays a central role in
hematological malignancies and in the pathogenesis of autoimmune
diseases, such as rheumatoid arthritis, systemic lupus
erythematosus, and inflammatory bowel disease. For more
information on the PathPro JAK-STAT panel, please visit http://nodality.com/products-standard-jak-stat.html.
|
|
|
|
|
|
|
|
|
|
•
|
|
PathPro™ TLR panel
|
|
|
|
|
|
|
|
|
|
|
|
Nodality offers the PathPro Toll-Like Receptor (TLR) panel for
evaluation of B cell subsets and monocytes. The panel is designed
to simultaneously measure signaling and compound activity in
different cell types in the context of TLR signaling. Tight
regulation of TLR-mediated signaling is critical for the
maintenance of healthy immune responses; aberrant signaling
through TLRs is associated with autoimmune disorders. For more
information on the PathPro TLR panel, please visit http://nodality.com/products-standard-tlr.html.
|
|
|
|
|
|
|
|
|
|
•
|
|
PathPro™ AML panels
|
|
|
|
|
|
|
|
|
|
|
|
Nodality is offering a PathPro Acute Myeloid Leukemia (AML)
Signaling and an AML Apoptosis panel. These panels can be used to
study the potency, MOA, specificity and response to treatment in
AML patients as single agents or in combinations. Nodality’s SCNP
platform has been used to characterize biological pathways
associated with in vitro resistance or sensitivity to
chemotherapeutics commonly used in AML. For more information on
the PathPro AML panels, please visit http://nodality.com/products-disease-offerings.html.
|
|
|
|
|
|
|
About Single Cell Network Profiling
Nodality’s proprietary Single Cell Network Profiling (SCNP)
technology, a multiparametric flow cytometry-based platform, provides
robust, human cell-based translational models of disease, drug activity
and patient responses. SCNP reveals complex biology by characterizing
cell signaling networks in millions of cells at the single cell level.
SCNP technology, coupled with Nodality’s proprietary data analysis and
visualization tools, uniquely reveals complex functional biology to
inform more effective drug development decisions thereby creating a
competitive advantage.
Originally developed at Stanford University, SCNP does not require
physical isolation of cell subsets and therefore provides real time
information on cell-cell interactions, identifies the functional
signaling capacity of rare cell subsets (such as drug-resistant cells
and stem cell populations) reveals the functional consequences of
epigenetic mutations and enables the interrogation of immune cell
communication and dysfunction in disease.
About Nodality
Nodality is a life science company whose technology platform, SCNP,
bridges the gap left by traditional R&D approaches. Nodality provides
clinically actionable solutions throughout the full discovery and
development process, including disease profiling, drug profiling,
clinical development, and life cycle management. Nodality’s team has
expertise in identifying solutions across a broad therapeutic landscape,
with a focus on immunology and oncology, including immuno-oncology.
Nodality has established multi-year strategic collaborations with UCB
Pharma S.A. (Euronext Brussels: UCB), Pfizer (NYSE: PFE) and Johnson &
Johnson (NYSE: JNJ), utilizing its SCNP technology to assist the
discovery and development of new therapeutic compounds. Major investors
include Kleiner Perkins, TPG Biotech, Maverick, Pfizer, and LabCorp.
For more information on Nodality, please visit www.nodality.com.
Copyright Business Wire 2015